Montag, 18. Dezember 2017


  • Pressemitteilung BoxID 19797

4SC AG: patient treatment in phase IIa clinical trial completed

Planegg-Martinsried, (lifePR) - German drug discovery and development company 4SC AG (Frankfurt, Prime Standard), based in Martinsried near Munich, announced today that the last patient was released from the current phase IIa clinical trial according to plan. With this event, the so-called "in-life-phase" of this study with the drug candidate SC12267 for the treatment of rheumatoid arthritis has been completed as scheduled.

In the three-tiered and placebo-controlled study, about 120 patients were given two doses of SC12267 per day over a three month period and tested for tolerance and clinical efficacy. The study was carried out in 13 centres across Germany, Poland and Serbia. The study results are expected for this quarter.

About Rheumatoid Arthritis:

Rheumatoid Arthritis is a chronic inflammatory joint disease that afflicts 0.5 - 1% of the population; women are three times more likely to get arthritis than men are. In the late stage of the disease, irreversible damage to joint cartilage and bones occurs. Causes of this disease are genetic as well as autoimmune factors. Besides pain-relieving medicines, so-called disease-modifying medicines (DMARDs = disease modifying anti-rheumatic drugs) can be used in treatment. These drugs are used to induce a healing process.

They differ from other groups of drugs used in the treatment of rheumatoid diseases, since only they are able to stop or reduce damage caused from chronic inflammation to the joint cartilage or bone. In the most favourable cases, some DMARDs can also induce repair of damage to joints and provide support for the repair of changes that have already occurred.

About SC12267:

SC12267 is a new type of small molecular active agent from the class of DMARDs used for treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The substance works as a highly selective inhibitor in the biosynthesis of pyrimidine, which inhibits the proliferation of fast proliferating cells, in particular the important lymphocytes used for immune response. The drug candidate originates in 4SC AG's own research pipeline. In prior pre-clinical and clinical studies, an outstanding potency and favourable pharmacokinetic characteristics could already be observed in animal testing, and a tolerable dosage without relevant side effects on test subjects was determined.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
Diese Pressemitteilung posten:

4SC AG

Die 4SC AG (ISIN DE0005753818) ist seit dem 15. Dezember 2005 im Prime Standard an der Frankfurter Wertpapierbörse gelistet. Das 1997 gegründete Unternehmen entwickelt mit derzeit 77 Mitarbeitern neuartige Wirkstoffe gegen Autoimmunerkrankungen und Krebs. Die 4SC AG nutzt dabei ihre patentgeschützte Technologieplattform, um eine nachhaltige Pipeline an Wirkstoffen aufzubauen. Diese sollen bis zum Nachweis der klinischen Wirksamkeit in frühen klinischen Phasen ('Proof of Concept') entwickelt und anschließend gegen Vorab- und Meilensteinzahlungen sowie Umsatzbeteiligungen in Partnerschaften mit der Pharmaindustrie eingebracht werden. Aktuell besteht die Pipeline aus acht Projekten sowie einem reichhaltigen Pool an weiteren Forschungsprojekten. Für ein Projekt zur Behandlung von Rheumatoider Arthritis wurde die klinische Phase IIa bereits erfolgreich beendet. Ein weiteres Projekt zur Behandlung verschiedener Krebserkrankungen befindet sich in der klinischen Phase I. Weitere Projekte durchlaufen bereits ein fortgeschrittenes Stadium der präklinischen Entwicklung.

Weitere Informationen finden Sie unter www.4sc.com.

Disclaimer